natgillin/translations-raw huggingface dataset:
Patienter co-inficeret med hepatitis B- og/eller hepatitis C-virus Der foreligger kun begrænsede oplysninger om brugen af komponenterne i Symtuza hos patienter, der er co-inficeret med hepatitis B og/eller hepatitis C-virus.
Patients co-infected with hepatitis B and/or hepatitis C virus Limited information is available on the use of Symtuza components in patients co-infected with hepatitis B and/or C virus.
Disse resultater blev tilskrevet de umodne leverenzymer og den umodne blod-hjernebarriere.
These findings were attributed to the immaturity of the liver enzymes and of the blood brain barrier.
Tenofoviralafenamid er virksomt over for hepatitis B-virus (HBV).
Tenofovir alafenamide is active against hepatitis B virus (HBV).
Med hensyn til monitorering af lipider og glucose i blodet henvises der til eksisterende behandlingsguidelines for hiv.
For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines.
Dosisjustering af buprenorphin er muligvis ikke nødvendig ved co-administration med Symtuza, men omhyggelig klinisk monitorering for tegn på opioidtoksicitet anbefales.
Dose adjustment for buprenorphine may not be necessary when co-administered with Symtuza, but a careful clinical monitoring for signs of opiate toxicity is recommended.
PHOSPHODIESTERASE TYPE 5 (PDE-5)-HÆMMERE Til behandling af erektil dysfunktion Sildenafil Tadalafil Vardenafil
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS For the treatment of erectile dysfunction Sildenafil Tadalafil Vardenafil
Autoimmune lidelser kan opstå, mange måneder efter påbegyndt behandling.
Autoimmune disorders may occur many months after the start of treatment.
Symtuza-tabletterne fås i pakninger med én beholder eller tre beholdere pr. karton.
The Symtuza tablets are available in packs containing one bottle or three bottles per carton.
I fase 3-studiet med Symtuza af behandlingsnaive patienter opstod der stigninger i serumkreatinin og fald i eGFRCG ved den første evaluering i behandling (uge 2) og forblev stabile over 96 uger.
In the Phase 3 trial of Symtuza in treatment-naïve patients, increases in serum creatinine and decreases in eGFRCG occurred at the first on-treatment assessment (Week 2) and remained stable through 96 weeks.
Omend ætiologien anses for at være multifaktoriel (herunder kortikosteroidbehandling, alkoholforbrug, alvorlig immunsuppression, højt BMI), er der rapporteret tilfælde af osteonekrose, især hos patienter med fremskreden hiv-sygdom og/eller langvarig eksponering for antiretroviral kombinationsbehandling (CART).
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to combination antiretroviral therapy (CART).
Både på grund af risikoen for hiv-transmission og på grund af risikoen for bivirkninger hos det ammede spædbarn skal moderen instrueres i ikke at amme, hvis hun behandles med Symtuza.
Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed if they are receiving Symtuza.
Dosisreduktion eller afbrydelse af behandlingen med colchicin anbefales hos patienter med normal nyre- og leverfunktion, hvis behandling med Symtuza er nødvendig.
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with Symtuza is required.
Udslættet var for det meste let til moderat og opstod ofte inden for de første fire ugers behandling og fortog sig under den fortsatte behandling (se pkt.
Rash was mostly mild to moderate, often occurring within the first four weeks of treatment and resolving with continued dosing (see section 4.4).
Det er påvist, at cobicistat nedsætter den estimerede kreatininclearance på grund af hæmning af den tubulære sekretion af kreatinin.
Cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine.
Den intravenøse clearance af darunavir alene (150 mg) og ved tilstedeværelse af lavdosis (100 mg) ritonavir var henholdsvis 32,8 l/t og 5,9 l/t.
The intravenous clearance of darunavir alone (150 mg) and in the presence of low dose (100 mg) ritonavir was 32.8 l/h and 5.9 l/h, respectively.
Det vides ikke, om emtricitabin eller tenofovir kan fjernes med peritonealdialyse.
It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.
ANTIMYKOTIKA Clotrimazol Fluconazol Itraconazol
ANTIFUNGALS Clotrimazole Fluconazole Itraconazole
En potentiel risiko for nefrotoksicitet som følge af kronisk eksponering over for lave koncentrationer af tenofovir på grund af dosering af tenofoviralafenamid kan ikke udelukkes (se pkt.
A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded (see section 5.3).
Co-administration af Symtuza med lægemidler, der primært metaboliseres af CYP3A, kan forårsage øget systemisk eksponering for sådanne lægemidler, hvilket kan øge eller forlænge både den terapeutiske virkning og bivirkninger.
Co-administration of Symtuza and medicinal products primarily metabolised by CYP3A may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Co-administration af emtricitabin med lægemidler, der elimineres ved aktiv tubulær sekretion, kan øge koncentrationerne af emtricitabin og/eller det samtidigt administrerede lægemiddel.
Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may increase concentrations of emtricitabine, and/or the co-administered medicinal product.
Lipidparameter Middelværdi ved baseline
Lipid Parameter Baseline Median
Rosuvastatin (10 mg en gang dagligt): rosuvastatin AUC ↑ 93 % rosuvastatin Cmax ↑ 277 % rosuvastatin Cmin ND
Rosuvastatin (10 mg once daily): rosuvastatin AUC ↑ 93% rosuvastatin Cmax ↑ 277% rosuvastatin Cmin ND
Symtuza bør ikke initieres hos patienter med eGFRCG< 30 ml/min, eftersom der ikke findes nogen data vedrørende brugen af Symtuza hos denne population (se pkt.
Symtuza should not be initiated in patients with eGFRCG < 30 mL/min, as there are no data available regarding the use of Symtuza in this population (see sections 5.1 and 5.2).
Baseline-CD4+-celletal <200 celler/mm ≥200 celler/mm
Baseline CD4+ cell count < 200 cells/mm ≥ 200 cells/mm
Dette er mere sandsynligt ved langvarig hiv-behandling, alvorlig svækkelse af immunforsvaret, ved overvægt eller brug af alkohol eller lægemidler, der kaldes kortikosteroider (binyrebarkhormoner).
This may be more likely with long-term HIV treatment, more severe damage to the immune system, being overweight, or the use of alcohol or medicines called corticosteroids.
Amiodaron Dronedaron Ivabradin Kinidin Ranolazin
Amiodarone Dronedarone Ivabradine Quinidine Ranolazine
Forsøgsdeltagere med PDVF, n (%)
Subjects with PDVF, n (%)
Fem forsøgsdeltagere forlod studiet af virkningsrelaterede årsager i henhold til investigators vurdering (lægens beslutning), hvoraf 3 havde sidste hiv-1 RNA under behandlingen < 50 kopier/ml.
Five subjects were discontinued from the study due to efficacy related reasons per investigator's assessment (physician decision), of which 3 had last on treatment HIV-1 RNA <50 copies/mL.
Du kan stadig smitte andre med hiv, selvom du tager dette lægemiddel, men risikoen reduceres med effektiv antiretroviral terapi (medicin mod retrovirus, f.eks. hiv).
You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy.
Brug af anden medicin sammen med Symtuza Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig.
Other medicines and Symtuza Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Kontakt lægen, før du tager Symtuza.
Talk to your doctor before taking Symtuza.
Brugen af Symtuza hos ART-naive unge patienter i alderen 12 år til < 18 år, og som vejer mindst 40 kg, understøttes af to studier af hiv-1-inficerede pædiatriske patienter (TMC114-C230 og GS-US-292-0106).
The use of Symtuza in ART-naïve adolescent patients from the age of 12 years to < 18 years, and weighing at least 40 kg is supported by two trials in HIV-1 infected paediatric patients (TMC114-C230 and GS-US-292-0106).
Det emtricitabin-resistente virus med M184M/IV/-mutation var krydsresistent over for lamivudin, men bevarede følsomheden over for abacavir, stavudin, tenofovir og zidovudin.
The emtricitabine-resistant virus with the M184M/I/V mutation was cross-resistant to lamivudine, but retained sensitivity to abacavir, stavudine, tenofovir, and zidovudine.
MALARIAMIDLER Artemether/lumefantrin
ANTIMALARIALS Artemether/Lumefantrine
Fortæl det til din læge, hvis du tager: - Bosentan (til behandling af for højt blodtryk i lungekredsløbet) - Dexamethason (injektion) (kortikosteroid) - Boceprevir (til behandling af hepatitis C-infektion) - Rifapentin, rifabutin (til behandling af bakterieinfektioner) - Oxcarbazepin (til forebyggelse af krampeanfald).
Tell your doctor if you take: - Bosentan (to treat high blood pressure in the pulmonary circulation) - Dexamethasone (injection) (corticosteroid) - Boceprevir (to treat hepatitis C virus infection) - Rifapentine, rifabutin (to treat bacterial infections) - Oxcarbazepine (to prevent seizures).
Sildenafil anvendes også til andre formål.
There are other uses for sildenafil.
Atorvastatin (10 mg en gang dagligt): atorvastatin AUC ↑ 290 % atorvastatin Cmax ↑ 319 % atorvastatin Cmin ND
Atorvastatin (10 mg once daily): atorvastatin AUC ↑ 290% atorvastatin Cmax ↑ 319% atorvastatin Cmin ND
Symtuzas sikkerhed og virkning hos patienter med samtidig hiv-1- og hepatitis C-virusinfektion (HCV) er ikke blevet klarlagt.
The safety and efficacy of Symtuza in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established.
• Fjern det løse låg.
• Remove the unscrewed cap.
I et flerdosisstudie med darunavir/ritonavir (600/100 mg) to gange dagligt blev det påvist, at den totale plasmakoncentration af darunavir hos forsøgspersoner med let (Child-Pugh klasse A, N=8) og moderat (Child-Pugh klasse B, N=8) nedsat leverfunktion var sammenlignelige med dem, der sås hos raske forsøgspersoner.
In a multiple dose trial with darunavir/ritonavir (600/100 mg) twice daily, it was demonstrated that the total plasma concentrations of darunavir in subjects with mild (Child-Pugh Class A, N = 8) and moderate (Child-Pugh Class B, N = 8) hepatic impairment were comparable with those in healthy subjects.
Den gennemsnitlige systemisk emtricitabineksponering var højere hos patienter med svært nedsat nyrefunktion (eGFRCG <30 ml/min) (33,7-μg•t/ml) end hos personer med normal nyrefunktion (11,8 μg•t/ml).
Mean systemic emtricitabine exposure was higher in patients with severe renal impairment (eGFRCG < 30 mL/min) (33.7 mcg•h/mL) than in subjects with normal renal function (11.8 mcg•h/mL).
Ingen virologiske data
No virologic data
Der findes ingen specifik antidot mod Symtuza.
There is no specific antidote for overdose with Symtuza.
Der foreligger rapporter om mitokondriel dysfunktion hos hiv-negative spædbørn, som har været eksponeret for nukleosidanaloger in utero og/eller efter fødslen.
There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues.
Formålet med lægemidlet
Purpose of the medicine
Når Symtuza co-administreres med et lægemiddel, som indeholder drospirenon, anbefales klinisk monitorering på grund af risikoen for hyperkaliæmi.
When Symtuza is coadministered with a drospirenone-containing product, clinical monitoring is recommended due to the potential for hyperkalaemia.
Cobicistats hæmning af CYP3A-medieret metabolisme øger den systemiske eksponering over for CYP3A-substrater såsom darunavir, hvor biotilgængeligheden er begrænset og halveringstiden forkortet på grund af den CYP3A-afhængige metabolisme.
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.
Co-administration af cobicistat med lægemidler, der er substrater for disse transportører, kan medføre øgede plasmakoncentrationer af de samtidigt administrerede lægemidler.
Co-administration of cobicistat with medicinal products that are substrates of these transporters can result in increased plasma concentrations of the co-administered medicinal products.
- Budesonid, fluticason (til behandling af astma).
- Budesonide, fluticasone (to control asthma).
Tretten procent af dosis blev genfundet i urinen som tre formodede metabolitter.
Thirteen percent of the dose was recovered in the urine as three putative metabolites.
DIREKTE VIRKENDE ANTIVIRALE MIDLER MOD HEPATITIS C (HCV) NS3-4A-hæmmere
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS NS3-4A inhibitors
Ca. 95 % af darunavir bindes til plasmaprotein.
Darunavir is approximately 95% bound to plasma protein.
Tag altid Symtuza nøjagtigt efter lægens eller apotekspersonalets anvisning.
Always take Symtuza exactly as your doctor or pharmacist has told you.
Kombinationen kan medføre øget risiko for kardiovaskulære bivirkninger med salmeterol, herunder QT-forlængelse, palpitationer og sinustakykardi.
The combination may result in increased risk of cardiovascular adverse events with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Ved uge 96 var middelændringen i eGFRCG -5,2 ml/min med D/C/F/TAF.
At Week 96, the median change in eGFRCG was -5.2 mL/min with D/C/F/TAF.
Symtuza kan øge risikoen for blødning.
Symtuza might increase the risk of bleeding.
Eksponeringen for darunavir og cobicistat administreret som Symtuza var henholdsvis 30-45 % og 16-29 % lavere i fastende sammenlignet med ikke-fastende tilstand.
The exposure to darunavir and cobicistat administered as the Symtuza was 30-45% lower and 16-29% lower, respectively, in fasted compared to fed condition.
Efter intravenøs administration var fordelingsvolumen for darunavir administreret alene 88,1 ± 59,0 l (gennemsnit ± SD) og steg til 131 ± 49,9 l (gennemsnit ± SD) ved kombination med 100 mg ritonavir to gange dagligt.
Following intravenous administration, the volume of distribution of darunavir alone was 88.1 ± 59.0 L (mean ± SD) and increased to 131 ± 49.9 L (mean ± SD) in the presence of 100 mg twice-daily ritonavir.
Symtuza kan co-administreres med H2-receptorantagonister uden dosisjusteringer.
Symtuza can be co-administered with H2-receptor antagonists without dose adjustments.
Der er øget risiko for sildenafil-relaterede bivirkninger (herunder synsforstyrrelser, hypotension, forlænget erektion og synkope).
There is an increased potential for sildenafil-associated adverse events (including visual disturbances, hypotension, prolonged erection and syncope).
Relevante eksempler omfatter cytomegalovirus retinitis, generaliserede og/eller fokale mykobakterielle infektioner og pneumoni forårsaget af Pneumocystis jirovecii (tidligere kendt som Pneumocystis carinii).
Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumonia caused by Pneumocystis jirovecii
Justering af methadondosis forventes ikke at være nødvendig, når co-administration med Symtuza påbegyndes.
No adjustment of methadone dosage is expected when initiating co-administration with Symtuza.
Symtuza er et lægemiddel, der anvendes til behandling af hiv-1-infektion (humant immundefekt virus 1).
Symtuza is an antiretroviral medicine used to treat infection with human immunodeficiency virus 1 (HIV-1).
Baseret på denne begrænsede erfaring forekommer sikkerhedsprofilen for emtricitabin/tenofoviralafenamid hos patienter co-inficeret med hiv/HBV at svare til den, der gælder for patienter, der kun er inficeret med hiv-1 (se pkt.
Based on this limited experience, the safety profile of emtricitabine/tenofovir alafenamide in patients with HIV/HBV co-infection appears to be similar to that in patients with HIV-1 monoinfection (see section 4.4).
Hos nogle patienter med fremskreden leversygdom eller skrumpelever (cirrose) kan en afbrydelse af behandlingen medføre en forværring af hepatitis, der kan være livstruende.
In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening.
Emtricitabins binding in vitro til humane plasmaproteiner var < 4 % og uafhængig af koncentrationen i intervallet 0,02-200 μg/ml.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 mcg/mL.
Se afsnittet 'Brug af anden medicin sammen med Symtuza'.
Please see section ‘Other medicines and Symtuza'.
Darunavir metaboliseres i udstrakt grad via det hepatiske CYPsystem og næsten udelukkende af isozym CYP3A4.
Darunavir is extensively metabolised by the hepatic CYP system and almost exclusively by isozyme CYP3A4.
• symptomer på infektion eller på autoimmune lidelser (immunrekonstitutionsinflammatorisk syndrom (IRIS))
• symptoms of infection or of autoimmune disorders (immune reconstitution inflammatory syndrome)
Da der foreligger begrænsede oplysninger om brug af Symtuza til patienter i alderen 65 år og derover, skal der udvises forsigtighed, hvilket afspejler den hyppigere forekomst af nedsat leverfunktion, samtidige sygdomme og andre behandlinger (se pkt.
As limited information is available on the use of Symtuza in patients aged 65 and over, caution should be exercised, reflecting the greater frequency of decreased hepatic function and of concomitant disease or other therapy (see sections 4.2 and 5.2).
De interaktioner, der er identificeret i studier med de individuelle komponenter i Symtuza, dvs. med darunavir (i kombination med lavdosis ritonavir), cobicistat, emtricitabin eller tenofoviralafenamid, er afgørende for, hvilke interaktioner der kan forekomme med Symtuza.
Interactions that have been identified in studies with individual components of Symtuza, i.e. with darunavir (in combination with low dose ritonavir), cobicistat, emtricitabine or tenofovir alafenamide, determine the interactions that may occur with Symtuza.
Den gennemsnitlige stigning fra baseline i CD4+-celletal ved uge 48 var 224 celler/mm
The mean increase from baseline in CD4+ cell count at Week 48 was 224 cells/mm
Alle symptomer på inflammation skal vurderes og behandling påbegyndes ved behov.
Any inflammatory symptoms should be evaluated and treatment instituted when necessary.
Der skal udvises forsigtighed ved co-administration af Symtuza og parenteral midazolam.
Caution should be used with co-administration of Symtuza and parenteral midazolam.
Poly(vinylalkohol) - delvist hydrolyseret Talcum
Poly (vinyl alcohol)- partially hydrolysed Talc
Lave niveauer af metabolitter blev genfundet i urin og fæces og bidrager ikke til cobicistats CYP3A-hæmmende aktivitet.
Low levels of metabolites are observed in urine and feces and do not contribute to the CYP3A inhibitory activity of cobicistat.
Under det kliniske udviklingsprogram med darunavir/ritonavir (N=3.063) rapporteredes hepatitis hos 0,5 % af de patienter, der fik antiretroviral kombinationsbehandling med darunavir/ritonavir.
During the darunavir/ritonavir clinical development program (N = 3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with darunavir/ritonavir.
Gul til gullig-brun kapselformet tablet på 22 mm x 11 mm, præget med „8121“ på den ene side og „JG“ på den anden side.
Yellow to yellowish-brown capsule shaped tablet of 22 mm x 11 mm, debossed with “8121” on one side and “JG” on the other side.
Nervesystemet meget almindelig hovedpine almindelig svimmelhed
Nervous system disorders very common headache common dizziness
Symtuza må derfor ikke kombineres med lægemidler, hvis clearance er meget afhængig af CYP3A, og for hvilke øget systemisk eksponering er forbundet med alvorlige og/eller livstruende bivirkninger (snævert terapeutisk vindue) (se pkt.
Symtuza, therefore, must not be combined with medicinal products that are highly dependent on CYP3A for clearance and for which increased systemic exposure is associated with serious and/or life-threatening events (narrow therapeutic index) (see section 4.3 or table below).
ANTIPSYKOTIKA/NEUROLEPTIKA Perphenazin
ANTIPSYCHOTICS/NEUROLEPTICS Perphenazine
H2-RECEPTORANTAGONISTER Cimetidin
H2-RECEPTOR ANTAGONISTS Cimetidine
Lurasidon Pimozid Quetiapin Sertindol
Lurasidone Pimozide Quetiapine Sertindole
Dyrestudier har påvist, at darunavir, cobicistat og tenofovir udskilles i mælk.
Studies in animals have demonstrated that darunavir, cobicistat and tenofovir are excreted in milk.
Der skal udvises forsigtighed, når clarithromycin kombineres med Symtuza.
Caution should be exercised when clarithromycin is combined with Symtuza.
Hvis samtidig brug af Symtuza og sildenafil, vardenafil eller tadalafil er indiceret, anbefales det at give en enkeltdosis sildenafil på højst 25 mg i løbet af 48 timer, en enkeltdosis vardenafil på højst 2,5 mg i løbet af 72 timer eller en enkeltdosis tadalafil på højst 10 mg i løbet af 72 timer.
If concomitant use of Symtuza with sildenafil, vardenafil or tadalafil is indicated, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 72 hours or tadalafil at a single dose not exceeding 10 mg in 72 hours is recommended.
Tag ikke Symtuza - hvis du er allergisk over for darunavir, cobicistat, emtricitabin, tenofoviralafenamid eller et af de øvrige indholdsstoffer i Symtuza (angivet i punkt 6).
Do not take Symtuza - if you are allergic (hypersensitive) to darunavir, cobicistat, emtricitabine, tenofovir alafenamide, or any of the other ingredients of Symtuza (listed in section 6).
celler/mm 3).
6 cells/mm 3).
Patienter med samtidigt forekommende tilstande
Patients with co-existing conditions
Sådan skal du tage Symtuza
How to take Symtuza
Middelændringen i eGFRCG var -5,5 ml/min med D/C/F/TAF og -12,0 ml/min med D/C+F/TDF (p=<0,001).
The median change in eGFRCG was -5.5 mL/min with D/C/F/TAF and -12.0 mL/min with D/C+F/TDF (p < 0.001).
Symtuzas sikkerhed hos pædiatriske patienter er ikke blevet undersøgt.
The safety of Symtuza in paediatric patients has not been investigated.
I fase 3-studiet med Symtuza af behandlingsnaive patienter sås der stigninger fra baseline i de fastende lipidparametre total kolesterol, direkte LDL- og HDL-kolesterol og triglycerider ved uge 48 og 96 (se tabel 3).
In the Phase 3 trial of Symtuza in treatment-naïve patients, increases from baseline were observed in the fasting lipid parameters total cholesterol, direct LDL and HDL cholesterol, and triglycerides at Week 48 and 96 (see Table 3).
I alt havde 22 % hiv-1 RNA i plasma ved baseline på >100.000 kopier/ml.
Overall, 22% had baseline plasma HIV-1 RNA > 100,000 copies/mL.
Cobicistat hæmmer transportørerne p-glykoprotein (P-gp), BCRP, MATE1, OATP1B1 og OATP1B3.
Cobicistat inhibits the transporters p-glycoprotein (P-gp), BCRP, MATE1, OATP1B1 and OATP1B3.
Efter 96 ugers behandling med Symtuza var de (95 % CI) procentvise ændringer i BMD i hofte- og rygradsregionen i forhold til baseline henholdsvis: -0,26 (0,96; 0,45) % og -0,93 (-1,82; -0,05) %.
After 96 weeks of treatment with Symtuza, the (95% CI) percent changes from baseline in BMD at the hip and spine region were respectively: -0.26 (-0.96; 0.45) % and -0.93 (-1.82; -0.05) %.
En sikker og effektiv dosis af sildenafil til behandling af pulmonal arteriel hypertension co-administreret med Symtuza er ikke fastlagt.
A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension co-administered with Symtuza has not been established.
C]-darunavir genfindes i henholdsvis fæces og urin.
C]-darunavir could be retrieved in faeces and urine, respectively.